These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 36976651)

  • 1. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
    Nichols DP; Morgan SJ; Skalland M; Vo AT; Van Dalfsen JM; Singh SB; Ni W; Hoffman LR; McGeer K; Heltshe SL; Clancy JP; Rowe SM; Jorth P; Singh PK;
    J Clin Invest; 2023 May; 133(10):. PubMed ID: 36976651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy.
    Hilliam Y; Armbruster CR; Rapsinski GJ; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Cooper VS; Lee SE; Bomberger JM
    Microbiol Spectr; 2024 Aug; 12(8):e0078724. PubMed ID: 38916354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence and evolution of
    Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
    mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
    Schaupp L; Addante A; Völler M; Fentker K; Kuppe A; Bardua M; Duerr J; Piehler L; Röhmel J; Thee S; Kirchner M; Ziehm M; Lauster D; Haag R; Gradzielski M; Stahl M; Mertins P; Boutin S; Graeber SY; Mall MA
    Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37414422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
    Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK
    mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare
    Lefferts JW; Bierlaagh MC; Kroes S; Nieuwenhuijze NDA; Sonneveld van Kooten HN; Niemöller PJ; Verburg TF; Janssens HM; Muilwijk D; van Beuningen SFB; van der Ent CK; Beekman JM
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.
    Cigana C; Giannella R; Colavolpe A; Alcalá-Franco B; Mancini G; Colombi F; Bigogno C; Bastrup U; Bertoni G; Bragonzi A
    Microbiol Spectr; 2023 Feb; 11(1):e0408322. PubMed ID: 36625583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis.
    Ledger EL; Smith DJ; Teh JJ; Wood ME; Whibley PE; Morrison M; Goldberg JB; Reid DW; Wells TJ
    J Infect Dis; 2024 Sep; 230(3):e536-e547. PubMed ID: 38442240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
    Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
    Respir Res; 2023 Dec; 24(1):317. PubMed ID: 38104128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis.
    Dittrich AM; Sieber S; Naehrlich L; Burkhart M; Hafkemeyer S; Tümmler B;
    Int J Infect Dis; 2024 Feb; 139():124-131. PubMed ID: 38036261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.
    Zhang S; Shrestha CL; Robledo-Avila F; Jaganathan D; Wisniewski BL; Brown N; Pham H; Carey K; Amer AO; Hall-Stoodley L; McCoy KS; Bai S; Partida-Sanchez S; Kopp BT
    Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 36265882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elexacaftor-Tezacaftor-Ivacaftor Therapy for Chronic Sinus Disease in Cystic Fibrosis.
    Sheikh S; Ho ML; Eisner M; Gushue C; Paul G; Holtzlander M; Johnson T; McCoy KS; Lind M
    JAMA Otolaryngol Head Neck Surg; 2023 Dec; 149(12):1075-1082. PubMed ID: 37676668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pediatric cystic fibrosis arthropathy case who responded to Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Arslan M; Bahadir Z; Basiaga ML; Chalmers SJ; Demirel N
    J Cyst Fibros; 2023 Nov; 22(6):1120-1122. PubMed ID: 37709627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
    Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
    Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized CFTR Modulator Therapy for
    Graeber SY; Balázs A; Ziegahn N; Rubil T; Vitzthum C; Piehler L; Drescher M; Seidel K; Rohrbach A; Röhmel J; Thee S; Duerr J; Mall MA; Stahl M
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.
    Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C
    Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
    Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
    Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.